Data Registry in Chinese Hemophilia A and B Patients

Data Registry in Chinese Hemophilia A and B Patients Related to the Use of Anti-hemophilic Coagulation Factor Replacement Therapy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07101224

Enrollment

200

Registered

2025-08-03

Start date

2017-05-07

Completion date

2019-06-30

Last updated

2025-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A, Hemophilia B

Keywords

anti-hemophilic coagulation factor replacement therapy

Brief summary

This is an open-label, prospective, multi-center, patient registry in Chinese Hemophilia A and B patients treated with anti-hemophilic coagulation factor replacement therapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

： Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study: 1. Hemophilia A and Hemophilia B patient diagnosed; 2. Taking anti-hemophilic coagulation factor replacement therapy during the 2 year registry period.

Exclusion criteria

1\. Unwilling or unable to follow the terms of the protocol.

Design outcomes

Primary

Measure	Time frame	Description
The incidence of MIEs and other SAEs	at the end of 2 year data registry	The incidence of MIE(medically important events)s and other SAE(serious adverse event)s in the anti-hemophilic replacement treatment

Secondary

Measure	Time frame	Description
Treatment regimen	at the end of 2 year data registry	Treatment regimen of anti-hemophilic replacement treatment

Countries

China

Outcome results